Your browser doesn't support javascript.
loading
Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt.
Saleh, Ahmed Mohamed; Hassan, Essam Ali; Gomaa, Ahmed Ali; El Baz, Tamer Mahmoud; El-Abgeegy, Mohamed; Seleem, Mohamed Ismail; Abo-Amer, Yousry Esam-Eldin; Elsergany, Heba Fadl; Mahmoud, Eman Ibrahim El-Desoki; Abd-Elsalam, Sherief.
Afiliação
  • Saleh AM; Tropical Medicine Department, Fayoum University, Al Fayyum, Egypt.
  • Hassan EA; Tropical Medicine Department, Fayoum University, Al Fayyum, Egypt.
  • Gomaa AA; Tropical Medicine Department, Fayoum University, Al Fayyum, Egypt.
  • El Baz TM; Endemic Medicine Department, Cairo University, Giza, Egypt.
  • El-Abgeegy M; Liver Transplantation Team, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
  • Seleem MI; Liver Transplantation Team, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
  • Abo-Amer YE; Hepatology, Gastroenterology, and Infectious Diseases Department, Mahala Hepatology Teaching Hospital, Gharbia, Egypt.
  • Elsergany HF; Liver Transplantation Team, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
  • Mahmoud EIE; Liver Transplantation Team, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
  • Abd-Elsalam S; Tropical Medicine Department, Tanta University, Tanta, Egypt.
Infect Drug Resist ; 12: 2277-2282, 2019.
Article em En | MEDLINE | ID: mdl-31413604
ABSTRACT
BACKGROUND AND

AIM:

Liver transplantation (LT) has emerged as an established therapeutic option for patients with chronic liver disease. Patients with end-stage liver disease are at high risk of infection with multidrug-resistant organisms, which may affect the outcome of LT. The aim of this study was to evaluate the impact of pre-transplant infection on the outcome of living-donor LT.

METHODS:

Prospective follow-up was done for 50 patients with chronic liver disease who had had LT performed from September 2013 to December 2017. We divided patients into group 1 (patients who had had infection within 3 months before transplantation with adequate treatment [n=20]), and group 2 (patients without infection [n=30]). Both groups were followed for 4 months post-operatively.

RESULTS:

Patients with high Model for End-Stage Liver Disease scores were more susceptible to infection pre- and post-operatively, and chest infection was the most common infection pre-transplant. There were no significant statistical differences regarding hospital and ICU stay and post-operative course between the groups, but the mortality rate was higher in group 1 (40%) than in group 2 (23.3%), and the causes of mortality in the group 1 were mainly due to medical causes (infections and sepsis, 75%) versus 28.6% in group 2.

CONCLUSION:

Liver-cell failure and concomitant infection 3 months before LT with adequate treatment had no significant statistical differences regarding hospital, ICU stay, or medical complications, but post-operative infection and mortality rate were more frequent in group 1 and the causes of mortality were mainly medical.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article